• DL-Dithiothreitol APJ receptors have a amino acid

  2023-12-19

  

  APJ receptors have a 380 amino DL-Dithiothreitol sequence with a characteristic G-protein structure, including seven transmembrane domains and post-translation modification sites for phosphorylation, palmitoylation and glycosylation along with association sites for β-arrestin (O'Dowd et al., 1993).

• At Johns Hopkins Aramco Health JHAH we started

  2023-12-19

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• br Angiotensin receptor neprilysin inhibitors Sacubitril val

  2023-12-19

  

  Angiotensin receptor-neprilysin inhibitors Sacubitril/valsartan is the first-in-class ARNI, comprising of molecular moieties of valsartan (ARB) and a neprilysin inhibitor prodrug, sacubitril (AHU377) [51]. Upon ingestion, sacubitril is rapidly metabolised into an active neprilysin inhibitor, sacu

• Calcium entry through postsynaptic NMDARs

  2023-12-19

  

  Calcium entry through postsynaptic NMDARs activates intracellular signaling cascades including Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) and calcineurin. The spatiotemporal abundance of this Ca2+/CaM complex determines the direction of synaptic plasticity, resulting in LTP (Malinow

• Introduction Rapeseed oil production is very important

  2023-12-19

  

  Introduction Rapeseed oil production is very important not only because of its application in food industry, but also in petrochemical branch. Additionally, post-extraction meal and bagasse from oilseed rape are important sources of proteins in animal feedstuffs production. Oilseed rape (Brassica n

• br Animal models of NAFLD

  2023-12-19

  

  Animal models of NAFLD Human research has greatly shaped our understanding of non-alcoholic fatty liver disease, but several limitations exist in studying the disease processes in humans, such as variations in environmental exposure, pre-existing genetic risk factors, racial and ethnic difference

• br Conflict of interest statement br

  2023-12-19

  

  Conflict of interest statement Introduction The global prevalence of Alzheimer's disease (AD) is expected to increase to 106 million in 2050 from 30 million in 2010 (Brookmeyer et al., 2007), which will further impose a significant economic burden on health systems and society as a whole (Broo

• The mechanism of transformation into SCLC

  2023-12-19

  

  The mechanism of transformation into SCLC is unclear but the loss of retinoblastoma gene (RB) seems important and constitutes an initial event in the tumorigenic process. Some reports revealed the role of the RB gene loss in EGFR mutated NSCLC who transformed into SCLC [15]. In NGS we retrieved mut

• Most of the identified aldose

  2023-12-19

  

  Most of the identified aldose reductase inhibitors possess undesirable effects like poor pharmacokinetic properties, hypersensitivity and Steven-Johnson Syndrome [1]. However, the main side effect is the lack of selectivity relative to aldehyde reductase (ALR1, EC 1.1.1.2). ALR1 plays the important

• AMPK is a serine threonine

  2023-12-18

  

  AMPK is a serine/threonine protein kinase composed of a catalytic α subunit with the activating phosphorylation site (Thr172) and two regulatory subunits, β and γ. The two AMPK variants, α1 and α2, show different cellular localization in mammalian cells. AMPKα2 is detected in nuclear and non-nuclear

• Toxicity is the main reason for the failure at

  2023-12-18

  

  Toxicity is the main reason for the failure at all stages of the new drug development process. The major part of safety-related attrition occurs at preclinical phases while predicting preclinical safety liabilities earlier in the drug development process. This strategy enables the design and/or sele

• br Material and methods br Results br Discussion Clinical ge

  2023-12-18

  

  Material and methods Results Discussion Clinical gene therapy trials with viral vectors have been in use for treatment of various genetic disorders and diseases, however efficacious, targetable and highly reliable non-viral delivery systems are needed for safe and long-term applications. De

• The presence of different LO splice variants was first

  2023-12-18

  

  The presence of different 5-LO splice variants was first demonstrated in human Rottlerin tumour cells and in dimethyl sulfoxide-differentiated HL-60 cells [40] and a correlation between the 5-LO splicing pattern and the malignancy of the brain tumours was found. Later, other splice variants were id

• In our H K ATPase assay Fig and

  2023-12-18

  

  In our H+, K+-ATPase assay (Fig. 1 and Supplementary Fig. 1), myricetin (IC50 = 0.58μM) was more potent than acid-activated omeprazole (IC50 = 1.50μM). In contrast, in oral administration in mice (Fig. 3), omeprazole (20mg/kg) more effectively inhibited gastric hiv fusion inhibitors secretion compar

• br Experimental section br Competing

  2023-12-18

  

  Experimental section Competing interests Author's contributions Acknowledgement This research is partially supported by a seed fund for the Center for Drug Discovery and Translational Research (LS) and a research grant by Fujifilm (VPS and LS). The Sponsors played no roles in study desig

16243 records 245/1083 page Previous Next First page 上5页 241242243244245 下5页 Last page